Answers are grounded in this paper and cite their sources.
The HBV genome has a very high mutation rate, which is why it is considered a highly variable virus, being able to produce different variants or quasi-species in the same host, differentiated by small mutations that favor the oncogenic potential of the virus, in addition to attenuating the immunogenicity and antigenicity. There are a large number of epidemiological findings and studies that suggest a relationship between genotypes and pre-core / core variants of the hepatitis B virus with the clinical course of infection and the response to different antiviral treatments.
No takes yet. Share an insight, caveat, or question.
Rodríguez et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: